GlycoSeLect
Dublin
About GlycoSeLect
GlycoSeLect specialises in the development and production of Recombinant Prokaryotic Lectins (RPLs), enhanced tools for the analysis and selective purification of glycosylated biomolecules. RPLs have a broad spectrum of applications across the life sciences in: - Basic R&D – Glycobiology & Glycoproteomics. - Biomarker Discover & Biomedical Diagnostics. - The Biopharmaceutical Industry. - Vaccines - Cosmetics GlycoSeLect's Recombinant Prokaryotic Lectins (RPLs) present significant advantages over existing commercially available lectins products including: - Simplified, rapid & cost effective production through recombinant expression in Escherichia coli. - High purity & consistent performance. - Genetically enhanced glycan binding properties (specificity & affinity). - Scalable production facilitating utilization for large scale applications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $529.2K
- Funding stage: Seed
- Last round: Seed (Oct 2017)
- Website: glycoselect.com
- Phone: +353877902652
Industries & Categories
Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/glycoselect-221284 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.